M. G. Lewis

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

This study shows that germline-targeting SCIVs can activate and expand B cells expressing V2-apex bnAb-like precursors in rhesus macaques.

RBD-62, a high-affinity ACE2 antagonist, limits SARS-CoV-2 replication in both upper and lower airways in rhesus macaques without blocking memory responses or causing anti-drug immunity.

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

This study identifies a new class of V2-directed cross-neutralizing antibodies targeting a cryptic epitope in occluded-open HIV and SIV Env trimers.

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

This study evaluates vaccine efficacy against SARS-CoV-2 Omicron in macaques, finding that both humoral and cellular immune responses are necessary for virologic control.

This paper shows that the synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates through various vaccination routes and dose regimens.

This study shows the SARS-CoV-2 Omicron variant causes less weight loss in hamsters than previous variants, suggesting reduced lower respiratory tract disease severity.

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

This study compares DNA and DNA+protein vaccines in rhesus macaques, finding that co-immunization with both induces stronger antibody responses and better control of SARS-CoV-2 infection.

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

This study evaluates a SARS-CoV-2 spike ferritin nanoparticle vaccine's effectiveness against B.1.1.7 and B.1.351 variants in hamsters, showing protection against disease and viral replication.

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

This study shows that SARS-CoV-2 vaccines induce neutralizing antibodies against SARS-CoV-1, SARS-CoV-2, and batCoVs in monkeys.

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

This paper demonstrates that SHIVs with bulky aromatic amino acid substitutions at Env375 replicate efficiently in rhesus macaques and can be used for preclinical HIV vaccine testing.

This study compares the immunogenicity of mRNA-LNP vaccines to protein vaccines in nonhuman primates, finding comparable or superior HIV-1 antibody responses.

Virus-antibody coevolution in rhesus macaques recapitulates developmental features of human antibodies.

This study evaluates the efficacy of the REGN-COV2 antibody cocktail in preventing and treating SARS-CoV-2 infection in rhesus macaques and hamsters, showing reduced virus load and pathological effects.

This study evaluates an intradermal DNA vaccine against SARS-CoV-2 in rhesus macaques, showing it induces immune responses and provides protection against viral challenge.